Post Profile






Daiichi, Glaxo set up Japan venture

Japanese drugmaker Daiichi Sankyo and British peer GlaxoSmithKline are to form a 50-50 joint venture to bring new vaccines to Japan. ||| Japanese drugmaker Daiichi Sankyo and British peer GlaxoSmithKline are to form a 50-50 joint venture to bring new vaccines to Japan, targeting an underdeveloped segment of the world's second-biggest prescription drug market. News of the venture, which will likely create the top player in the Japanese vaccine market, sent shares of Japan's No.
read more

share

Related Posts:


Drugmakers Lundbeck, Otsuka form global alliance | Reuters

Medical / Pharmaceutical : PharmaGossip (3 years ago)

TOKUSHIMA, Japan/COPENHAGEN - Japanese drugmaker Otsuka Holdings Co and Danish peer Lundbeck are to jointly develop and sell up to five psychiatric and neuroscience drugs in a deal seen offering their pipelines a much-needed boost. ... Read Post

Daiichi Sankyo in friendly takeover of Ranbaxy

Medical / Pharmaceutical : PharmaGossip (7 years ago)

Daiichi Sankyo is buying control of India’s Ranbaxy Laboratories in a friendly takeover that could be worth as much as $4.6 billion.Under the terms of the deal, the Japanese drugmaker will acquire the 34.8% controlling stake of Ranb... Read Post

Daiichi Sankyo to buy Plexxikon | The Japan Times Online

Medical / Pharmaceutical : PharmaGossip (4 years ago)

Pharmaceutical giant Daiichi Sankyo Co. said Tuesday it has reached an agreement to wholly acquire Plexxikon Inc., a California-based drugmaker, for $805 million (about ¥66 billion) to strengthen its research and development of canc... Read Post

Comments


Copyright © 2015 Regator, LLC